Amarin's Q1 Revenue Climbs 7% to $45.1M, Narrows Net Loss to $10.5M
summarizeSummary
Amarin reported strong first-quarter 2026 results, with net revenue increasing 7% year-over-year to $45.1 million and the GAAP net loss significantly narrowing to $10.5 million. The company also achieved positive cash flow for the second consecutive quarter, demonstrating improved financial health. These results build on the narrative from the recent 10-K, which highlighted a global restructuring and European licensing agreement, indicating successful execution of strategic initiatives. The positive performance was driven by higher international sales and resilient U.S. branded VASCEPA prescriptions, alongside materially reduced operating expenses. Traders should note the continued operational improvements and watch for further updates on the European commercial rollout and the impact of the commercial model shift on future quarters.
At the time of this announcement, AMRN was trading at $13.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $290.5M. The 52-week trading range was $9.44 to $20.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.